Shanghai Pharma Acquires Majority Stake in JV Techpool in $280 Million Deal

Shanghai Pharma, together with Guangzhou Industrial Investment Fund Management, will pay $280 million to acquire Takeda's majority stake in their China JV, Guangdong Techpool Bio-Pharma. Currently, Takeda owns 52% of Techpool. After the transaction, Shanghai Pharma will own 67% of Techpool, and the Guangzhou Fund 25% (another arm of the Fund already owns 8%). Despite the sale, Takeda remains committed to China and plans to introduce up to seven innovative products in China over the next five years. More details.... Stock Symbols: (SHA: 601607; HK: 2607) (TSE: 4503) Share this with colleagues: // //